Skip to main content

Table 2 Univariate and multivariate analysis of the associations between LIPI and clinical outcomes of LS-SCLC

From: Prognostic ability of lung immune prognostic index in limited-stage small cell lung cancer

Variables

OS

PFS

Univariate

Multivariate

Univariate

Multivariate

P-value

HR (95%CI)

P-value

P-value

HR (95%CI)

P-value

Age

0.027

  

0.071

  

Gender

0.001

0.620(0.466–0.825)

0.001

0.006

0.701(0.542–0.905)

0.007

Smoke

0.017

  

0.028

  

ECOG

0.055

  

0.002

1.547(1.19–2.012)

0.001

AJCC TNM 8th

0.001

  

0.01

  

CT cycles

< 0.001

2.023(1.61–2.542)

< 0.001

< 0.001

1.482(1.183–1.855)

0.001

RT

< 0.001

1.546(1.234–1.937)

< 0.001

< 0.001

1.296(1.046–1.606)

0.018

PCI

< 0.001

0.455(0.297–0.696)

< 0.001

< 0.001

0.548(0.394–0.764)

< 0.001

LIPI

< 0.001

1.377(1.114–1.702)

0.003

< 0.001

1.338(1.1–1.626)

0.004

  1. LS-SCLC limited-stage small cell lung cancer, LIPI lung immune prognostic index, ECOG The Eastern Cooperative Oncology Group performance status, AJCC TNM 8th the 8th edition of the TNM staging system, CT chemotherapy, RT radiotherapy, PCI prophylactic cerebral irradiation, OS overall survival, PFS progression-free survival, HR hazard ratio, CI confidence interval
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us